Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 31:11:1168.
doi: 10.3389/fphar.2020.01168. eCollection 2020.

Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress

Radoslaw Magierski  1 , Tomasz Sobow  2 , Emilia Schwertner  3 , Dorota Religa  3   4
Affiliations
Review

Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress

Radoslaw Magierski et al. Front Pharmacol. .

Abstract

The core symptoms of different dementia subtypes are the behavioral and psychological symptoms of dementia (BPSD) and its neuropsychiatric symptoms (NPS). BPSD symptoms may occur at any stage in the case of dementia due to Alzheimer's disease (AD), whereas they tend to occur early on in the case of its behavioral variant frontotemporal dementia or dementia with Lewy bodies and are essential for diagnosis. BPSD treatment consists of non-pharmacological as well as pharmacological interventions, with non-pharmacological interactions being suggested as first-line treatment. Agitation, psychotic features, apathy, depression, and anxiety may not respond to acetylcholinesterase inhibitors or memantine in AD cases; therefore, antipsychotics, antidepressants, sedative drugs or anxiolytics, and antiepileptic drugs are typically prescribed. However, such management of BPSD can be complicated by hypersensitivity to antipsychotic drugs, as observed in DLB, and a lack of effective pro-cognitive treatment in the case of frontotemporal dementia. The present paper reviews current knowledge of the management of BPSD and its limitations and discusses on-going clinical trials and future therapeutic options.

Keywords: antidepressants; antipsychotics; behavioral and psychological symptoms of dementia; clinical trial; neuropsychiatric symptoms; non-pharmacological interventions.

PubMed Disclaimer

References

    1. Abraha I., Rimland J. M., Trotta F. M., Dell’Aquila G., Cruz-Jentoft A., Petrovic M., et al. (2017). Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. BMJ Open 7 (3), e012759. 10.1136/bmjopen-2016-012759 - DOI - PMC - PubMed
    1. Azermai M., Petrovic M., Elseviers M. M., Bourgeois J., Van Bortel L. M., Vander Stichele R. H. (2012). Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Res. Rev. 11 (1), 78–86. 10.1016/j.arr.2011.07.002 - DOI - PubMed
    1. Baillon S. F., Narayana U., Luxenberg J. S., Clifton A. V. (2018). Valproate preparations for agitation in dementia. Cochrane Database Syst. Rev. 10, CD003945. 10.1002/14651858.CD003945.pub4 - DOI - PMC - PubMed
    1. Ballard C., Orrell M., Sun Y., Moniz-Cook E., Stafford J., Whitaker R., et al. (2017). Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD—a factorial cluster randomised controlled trial. Int. J. Geriatr. Psychiatry 32, 1094–1103. 10.1002/gps.4572 - DOI - PubMed
    1. Ballard C., Banister C., Khan Z., Cummings J., Demos G., Coate B., et al. (2018). Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 17 (3), 213–222. 10.1016/S1474-4422(18)30039-5 - DOI - PubMed

LinkOut - more resources